Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2021-07-01 Regulatory Filings
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
기타경영사항(특허권취득)(자율공시)(항 α-syn 항체 및 그 용도)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from ABL Bio regarding the acquisition of a patent ('항 α-syn 항체 및 그 용도'). It follows the standard format for a voluntary corporate disclosure (자율공시) in the Korean market, detailing the patent name, content, and strategic application. Since it does not fit into specific categories like financial reports, M&A, or director dealings, it falls under the general regulatory filing category.
2021-07-01 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements (stock-backed loans) of major shareholders and their special related parties. This type of filing is specifically categorized as a Major Shareholding Notification (MRQ) in the provided schema.
2021-06-29 Korean
기타경영사항(특허권취득)(자율공시)(a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도)
Regulatory Filings Classification · 96% confidence The document is a voluntary disclosure ('자율공시') regarding the acquisition of a patent ('특허권 취득') by ABL Bio. It details the patent name, content, and strategic utilization plan. Since this is a specific regulatory announcement regarding corporate business developments that does not fit into financial reporting, dividend, or management change categories, it is classified as a general regulatory filing.
2021-06-07 Korean
투자판단관련주요경영사항(이중항체 항암제 ABL001의 제1a상 임상시험 결과)
Legal Proceedings Report Classification · 95% confidence The document is a formal regulatory disclosure filed with the Korea Exchange (KRX) regarding the results of a Phase 1a clinical trial for a drug candidate (ABL001). It details the trial methodology, safety results, and efficacy findings. In the context of Korean corporate filings, '투자판단 관련 주요경영사항' (Major Management Matters related to Investment Decisions) is a standard regulatory disclosure format used for material events, including clinical trial results. Since it does not fit into specific categories like financial reports or board changes, and is a direct regulatory filing of material information, it is classified as a Regulatory Filing (RNS).
2021-05-27 Korean
투자판단관련주요경영사항(이중항체 면역항암제 ABL501의 국내 제1상 임상시험계획 (IND) 신청)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from ABL Bio regarding the submission of an Investigational New Drug (IND) application for a clinical trial (ABL501). It details the clinical trial design, objectives, and regulatory status. Since this is a specific regulatory announcement regarding a material business event (clinical trial progress) that does not fit into categories like financial reports, dividends, or M&A, it is classified as a general regulatory filing.
2021-05-20 Korean
투자판단관련주요경영사항(TRIGR Therapeutics에 대한 5개 항암제 후보 물질 기술이전 계약의 해지)
M&A Activity Classification · 100% confidence The document is a regulatory filing from ABL Bio regarding the termination of a technology transfer agreement with TRIGR Therapeutics. It details the cancellation of a licensing contract for five anti-cancer drug candidates and the subsequent return of rights to the company. This type of disclosure regarding material business events, such as contract terminations, falls under general regulatory announcements.
2021-05-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.